NSC112372 | 500356-48-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: NSC112372
• 英文别名: Bromomethyl 6,8-dichloro-2-phenyl-4-quinolyl ketone；2-bromo-1-(6,8-dichloro-2-phenylquinolin-4-yl)ethanone
• CAS: 500356-48-9
• 化学式: C₁₇H₁₀BrCl₂NO
• 分子量: 395.082
• InChiKey: NGISGKUBMNKMGS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  30
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  NSC112372 生成 (6,8-Dichlor-2-phenyl-4-chinolyl)-ethylenoxid
  参考文献：
  名称：

  抗疟药。光毒性的2-苯基-4-喹啉二甲醇的类似物。

  摘要：

  DOI：

  10.1021/jm00312a027
• 作为产物：
  描述：

  6,8-dichloro-2-phenyl-quinoline-4-carbonyl chloride 在 重氮甲烷 、 二氯甲烷 作用下， 生成 NSC112372
  参考文献：
  名称：

  抗疟药；7-氯-4-羟基-和4,7-二氯-1-甲基甲硫基。

  摘要：

  DOI：

  10.1021/ja01213a041

文献信息

• REPROGRAMMING EFFECTOR PROTEIN INTERACTIONS TO CORRECT EPIGENETIC DEFECTS IN CANCER
  申请人：British Columbia Cancer Agency Branch

  公开号：EP2819662B1

  公开（公告）日：2019-04-10
• US9552457B2
  申请人：——

  公开号：US9552457B2

  公开（公告）日：2017-01-24
• [EN] EPIGENETIC REGULATORS AND USES THEREOF<br/>[FR] RÉGULATEURS ÉPIGÉNÉTIQUES ET UTILISATIONS ASSOCIÉES
  申请人：BRITISH COLUMBIA CANCER AGENCY

  公开号：WO2013059944A1

  公开（公告）日：2013-05-02

  Protein chromobox homolog 2 (CBX2) is provided as a target for the development of therapeutics for the treatment of diseases associated with a hyperactive polycomb 2 complex (PRC2), such as lymphomas, lung cancer, breast cancer, prostate cancer and cancers of the neurological system. Compounds of general Formula (I) suitable for use as therapeutics for the treatment of diseases associated with a hyperactive PRC2, for example, diseases characterized by hypermethylation activity of EZH2, are provided. Formula (I)
• [EN] REPROGRAMMING EFFECTOR PROTEIN INTERACTIONS TO CORRECT EPIGENETIC DEFECTS IN CANCER<br/>[FR] REPROGRAMMATION D'INTERACTIONS ENTRE PROTÉINES EFFECTRICES POUR CORRIGER DES DÉFAUTS ÉPIGÉNÉTIQUES DANS LE CANCER
  申请人：BRITISH COLUMBIA CANCER AGENCY

  公开号：WO2013127011A1

  公开（公告）日：2013-09-06

  Methods of "reprogramming" epigenetic mark readers or erasers to recognize epigenetic marks other than their cognate (or natural) marks are provided. Reprogramming the reader or eraser can offset the effects of aberrant writer activity (for example, loss of function or overactivity) that can contribute to certain diseases states, such as cancer. The use of the reprogramming compounds identified by these methods in the treatment of such disease states is also provided. Exemplary mark readers that can be targeted by these methods include BPTF and CBX2.
• Antimalarials. 7-Chloro-4-hydroxy- and 4,7-Dichloro-1-methylcarbostyrils¹
  作者：Robert E. Lutz、John F. Codington、Russell J. Rowlett、Adolf J. Deinet、Philip S. Bailey

  DOI：10.1021/ja01213a041

  日期：1946.9